Shanghai Junshi Biosciences (HKG:1877) reported that loss attributable to owners for 2024 narrowed by 44% to 1.28 billion yuan, from the 2.28 billion yuan loss a year earlier, according to a Thursday filing with the Hong Kong bourse.
Loss per share was 1.30 yuan, from 2.32 yuan loss per share a year ago.
Revenue rose 30% to 1.95 billion yuan from 1.50 billion yuan the previous year.
The company's shares were up 6% at the Hong Kong bourse and 2% at the Shanghai bourse in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。